ArticleFoods (Basel, Switzerland)2025
Mung Bean Peptides Alleviate Dextran-Sulfate-Sodium-Induced Colitis Symptoms in Mice by Protecting the Intestinal Mechanical Barrier and Regulating Gut Microbiota.
Article in Foods (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Consumer Rejection Threshold of Mung Bean Protein Hydrolysate: Unsweetened and Sweetened Brewed Teas as Test Models.Foods (Basel, Switzerland) · 2026Article
- Combined Prebiotic Extract of Mung Bean, Red Bean, and Fennel Improves Intestinal Barrier Integrity in HT-29 Cells and DSS-Induced Colitis via Gut Microbiota Alteration.Current issues in molecular biology · 2025Article
- Recent advances in bioactive peptides from fermented plant-based foods and their bioactivities.Food chemistry: X · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ulcerative colitis (UC), an idiopathic and recurrent ailment, substantially influences a patient's health. Mung bean peptides (MBPs) are bioactive substances derived from mung bean protein that possess notable anti-inflammatory properties. However, their efficacy and underlying mechanisms in UC treatment remain unclear. In this study, the structural characteristics of MBPs were examined by determining various parameters, such as amino acid composition, molecular weight distribution, and peptide sequences, thereby structurally demonstrating their anti-inflammatory potential. The therapeutic effectiveness of MBPs in UC treatment was evaluated by assessing its influence on colon length, histological damage to colonic tissue, and disease activity index of mice suffering from colitis induced by dextran sulfate sodium (DSS). Additionally, the study explored the potential mechanism of action of MBPs in UC by analyzing the intestinal microbiota, inflammatory cytokines in serum, and tight junction (TJ) proteins in the colon tissue of mice. The results revealed that MBPs significantly increased colon length, reduced colonic tissue damage, and decreased the disease activity index in mice with UC. MBPs restored intestinal barrier function by upregulating the expression of ZO-1 and claudin-1 proteins within the colonic tissue of mice with DSS-induced colitis, thereby treating UC. MBPs exerted anti-inflammatory effects by downregulating the amplification of inflammatory cytokines in the serum, improving the gut microbiota structure in mice with colitis, and regulating immune-related signaling pathways. Therefore, there is an experimental basis for the potential use of MBPs as adjunctive therapy in UC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.